1103738-26-6

Basic information

• Product Name: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone
• Synonyms: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone;(2-chloro-5-iodophenyl)(4-ethoxyphenyl)methanone;Methanone,(2-chloro-5-iodophenyl)(4-ethoxyphenyl)-
• CAS NO: 1103738-26-6
• Molecular Formula: C₁₅H₁₂ClIO₂
• Molecular Weight: 386.61205
• Mol File: 1103738-26-6.mol

Chemical Properties

• Boiling Point: 461.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.597±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone(1103738-26-6)
• EPA Substance Registry System: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone(1103738-26-6)

Safety Data

• Hazardous Substances Data: 1103738-26-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone is utilized as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone serves as a starting material or a building block for the development of new drugs. Its potential pharmaceutical applications are being explored for the treatment of various medical conditions, leveraging its chemical properties to target specific biological pathways or receptors.
Used in Pharmaceutical Development:
(5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone is employed as a precursor in the development of innovative pharmaceuticals. Its unique structural features contribute to the design of novel therapeutic agents that can address unmet medical needs or improve upon existing treatments.
Used in Material Science:
Due to its distinct chemical and physical properties, (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone may also find applications in material science. Its potential uses could include the development of new materials with specific characteristics, such as improved stability, reactivity, or selectivity in various chemical processes.
Used in Chemical Engineering:
In chemical engineering, (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone could be applied in the design and optimization of chemical processes. Its unique properties may contribute to enhancing process efficiency, selectivity, or the development of new methodologies for chemical production.

Upstream product

• 281652-58-2 2-chloro-5-iodobenzoylchloride 
• 103-73-1 Phenetole 
• 915095-86-2 (2-chloro-5-iodophenyl)(4-fluorophenyl)methanone 
• 141-52-6 sodium ethanolate 
• 917-58-8 potassium ethoxide 
• 2388-07-0 lithium ethoxide 
• 19094-56-5 2-chloro-5-iodobenzoic acid 
• 64-17-5 ethanol 
• 462-06-6 fluorobenzene 

Downstream Products

• 1103738-29-9 1-chloro-2-(4-ethoxybenzyl)-4-iodobenzene 
• 1018899-04-1 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2-H-pyran-3,4,5-triol 
• 1018899-03-0 [(2S,3S,4R,5S,6R)-4,5-diacetoxy-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylthiotetrahydropyran-3-yl]acetate 
• 1018898-84-4 acetic acid (3S,4R,5S,6S)-2,4,5-triacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydropyran-3-yl ester 
• 1103738-30-2 (4-chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuran[2,3-d][1,3]dioxolan-5-yl)methanone 
• 1459754-40-5 (2-chloro-5-iodophenyl)(4-hydroxyphenyl)methanone 
• 1417573-74-0 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucopyranoside 
• 915095-99-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-trityl triacetate 
• 1079083-63-8 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-hydroxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 461432-25-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 461432-26-8 dapagliflozin 

Relevant articles and documents

Design, synthesis and anticancer activities of halogenated Phenstatin analogs as microtubule destabilizing agent

A series of halogenated Phenstatin analogs were designed as microtubule destabilizing agent by docking study. It was synthesized within three steps starting from 2-chloro-5-iodobenzoic acid and substituted benzene. All the products were characterized by 1H NMR and 13C NMR spectral analysis, and the stereochemical structure was also confirmed by a single crystal X-ray diffraction crystallographic analysis. The microtubule destabilizing activities were evaluated in vitro with human liver cancer Huh-7 cell line and human lung cancer A549 cell line. Some of the HPAs were achieved IC50 about 5.0 μM against human liver cancer Huh-7 cells. [Figure not available: see fulltext.].

Stereoselective Palladium-Catalyzed Arylation of Exo-Glycals with Aryl Iodides

A novel methodology for the arylation of exo-glycals has been developed. A range of exo-glycals underwent reactions with aryl iodides in the presence of a palladium catalyst. The transformation proceeded in a stereoselective manner to afford Z-isomers. Th

Facile Approach to C-Glucosides by Using a Protecting-Group-Free Hiyama Cross-Coupling Reaction: High-Yielding Dapagliflozin Synthesis

Access to unprotected (hetero)aryl pseudo-C-glucosides via a mild Pd-catalysed Hiyama cross-coupling reaction of protecting-group-free 1-diisopropylsilyl-d-glucal with various (hetero)aryl halides has been developed. In addition, selected unprotected pseudo-C-glucosides were stereoselectively converted into the corresponding α- and β-C-glucosides, as well as 2-deoxy-β-C-glucosides. This methodology was applied to the efficient and high-yielding synthesis of dapagliflozin, a medicament used to treat type 2 diabetes mellitus. Finally, the versatility of our methodology was proved by the synthesis of other analogues of dapagliflozin.

Preparation method of polysubstituted diphenyl ketone

The preparation method comprises the following steps: (1) a compound represented by the formula II and a compound shown III as a raw material; and synthesizing the compound as shown IV. (2) The compound of Formula IV is subjected to Fries rearrangement to produce a compound of Formula V. (3) A compound of Formula V is subjected to a halogenation reaction in contact with a halogenation reagent to prepare a multi-substituted diphenyl ketone represented by Formula I. Wherein, X is selected from H, F, Cl, Br, I. R1 Selected H from F Cl, Br I are RO selected R from H, C1 - C6. X is selected from F, Cl, Br, and i. The present invention is capable of improving the yield and selectivity of the target product.

Process development of sotagliflozin, a dual inhibitor of sodium- Glucose cotransporter-1/2 for the treatment of diabetes

The development of an efficient manufacturing process for sotagliflozin (LX4211), a dual inhibitor of sodium- glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described. Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety. Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche reduction (dr: 97/3), dynamic kinetic resolution of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/ 1). Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystallization furnishes sotagliflozin. The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%. This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.

A SGLT2 inhibitor intermediates preparation method (by machine translation)

The invention discloses a SGLT2 inhibitor intermediates preparation method, comprises the following steps: (1) 5 - halo - 2 - chlorobenzoic acid and fluorobenzene to Friedel-crafts reaction, to obtain (5 - halo - 2 - chlorophenyl) (4 - fluorophenyl) a ketone; (2) under the action of the inorganic base, (5 - halo - 2 - chlorophenyl) (4 - fluorophenyl) methanone and ethanol undergo the substitution reaction, after the reaction is finished after treatment to obtain (5 - halo - 2 - chlorophenyl) (4 - ethoxy) a ketone; (3) (5 - halo - 2 - chlorophenyl) (4 - ethoxy) methanone in the reducing agent under the effect of the reduction reaction of carbonyl, get said SGLT2 inhibitor intermediates. The preparation method is through adopting the inorganic alkali and ethanol instead of the ethoxide reagent and DMSO (or DMF), not only can effectively reduce the cost, but also more environmentally friendly. (by machine translation)

COMPOSITIONS COMPRISING (2S,3R,4R,5S,6R)-2-(4- CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL

Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN

The present invention discloses a novel process for the preparation of Dapagliflozin (S)-propylene glycol hydrate of Formula II. (Formula II)

SGLT-2 inhibitor intermediate synthesis method

The invention discloses a SGLT-2 inhibitor intermediate synthesis method. The method utilizes a NaBH4-TMSCl complex reducing agent to reduce carbonyl into methylene. The synthesis method has the characteristics of less side reactions, good environmental friendliness, low price, use of easily available raw materials and large scale production feasibility.

Preparation method of SGLT2 inhibitor intermediate

The invention provides a preparation method of an SGLT2 inhibitor intermediate II. The preparation method includes that a compound V and an ethoxide reagent are subjected to nucleophilic substitution in a proper solution to obtain a compound II, wherein the compounding formula is shown as below, and X in the compound V structure is selected from Br or I. By the compounding route, the problem of purification difficulty caused by plenty of isomers in compounding routes in documentary reports is solved. Reaction operations are simple and convenient, the reagent is low in cost and easy to get, and the obtained product does not contain the isomers. The route is suitable for industrial production.